4. Comparison of median survival: cisplatin combination including or excluding a taxane.

Study	Cisplatin + other			Cisplatin + taxane			P value
	n	Median OS (months)	Median PFS (months)	n	Median OS (months)	Median PFS (months)
Monk 2008 CV vs. CT vs. CG vs. CP	117 (CV) 118 (CT) 119 (CG)	10‐10.3	4.9 (CV) 4.6 (CT) 4.7 (CG)	118 (CP)	12.9	5.8	ns
Mountzios 2009 CI vs. CIP	74 (CI)	13.2	6.3	79 (CIP)	15.4	7.9	0.048 (OS) 0.023 (PFS)

CG: cisplatin/gemcitabine; CI: cisplatin/ifosfamide; CIP: cisplatin/ifosfamide/paclitaxel; CP: cisplatin/paclitaxel; CT: cisplatin/topotecan; CV: cisplatin/vinorelbine; OS: overall survival; PFS: progression‐free survival; ns: not significant